Toggle menu

DASH Trial

Start date:
June 2019

Why?

Medications to ‘thin’ the blood can have an unwanted effect on strokes caused by bleeding in the brain. Controlling bleeding is crucial in the first few hours after stroke but there is still uncertainty over the best course of treatment.

 

What?

DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.

 

https://clinicaltrials.gov/ct2/show/NCT03696121

Research Team

Allan MacRaild

Stroke Lead Research Nurse

Seona Burgess

Senior Stroke Research Nurse

Pat Taylor

Senior Stroke Research Nurse

Rachel O'Brien

Lead Research Nurse

Julia Grahamslaw

Lead Research Nurse

Fiona McCurrach

Senior Research Nurse

More EMERGE Trials

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.

Read more

TARGET-CTCA Trial

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2 Trial

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)